Diamune is a biotech company developing novel therapeutics for the Prevention and Treatment of Type 1 Diabetes. Its innovative IgG Fc-Fusion insulin analogs are meticulously engineered to prevent autoimmune diabetes via immune modulation in pre-diabetic individuals, while others are designed as a “once-a-week” Ultra Long-Acting Insulin treatment to elevate standards of diabetes management.

• Two decades of experience and success in the biopharma industry and academic research environments that includes an extensive network of first-hand professional relationships with key opinion leaders• Provides scientific and business expertise with start-up biotech companies in drug discovery/development of immunology- & inflammation-based therapeutics, especially those for autoimmune diseases with emphasis on type 1 diabetes• Creates therapeutic development and business plans suitable for generating investment funds by constructing value propositions that support a practical goal-oriented plan.- Establishes therapeutic development strategic and tactical plan (therapeutic rationale, preclinical structure, clinical progression)- Develops business plan including financials, management design, value inflection timeline - Develops and executes funding strategy (e.g., facilitate clinical support from consortia)• Creates and presents pitch deck with company management to funding organizations• Non-dilutive financing: Prepares Grant proposals (NIH SBIR and foundation grants)

A biotech start-up focused on a novel vaccine delivery system

IM Therapeutics is a clinical-stage company pioneering personalized, oral medicines that target human leukocyte antigen (HLA) gene variants to treat the root cause of autoimmune diseases.

Akston Biosciences Corporation is a leader in the field of insulin engineering and COVID-19 vaccine development. The company was founded in 2011 by the former SmartCells, Inc. team who developed the world’s first clinical glucose-responsive insulin (acquired by Merck & Co. in 2010). Combining its core expertise with modern biotechnology manufacturing techniques, Akston is developing new classes of biologic therapeutics for use in autoimmune Type 1 diabetes prevention, ultra-long acting insulin therapy, and oncology to dramatically improve both human and animal health. In addition, its core Fc-fusion protein technology and GMP production facility is facilitating development of a novel COVID-19 vaccine.

• At the Juvenile Diabetes Research Foundation (JDRF), led the type 1 diabetes (T1D) immunotherapies program and portfolio that drove a therapeutic research and development pipeline aimed at delivering novel Immune Modulation therapies for the prevention and treatment of T1D• Created and executed strategies for developing effective and innovative immunotherapies for T1D, including partnering with biotechnology and pharmaceutical companies and managing an academic research portfolio (leveraging experiences with therapies from other autoimmune indications)• Translational research/medicine: Developed Biomarker discovery and assay development initiatives• Organizational leadership: created and implemented portfolio analysis system for evaluating and measuring progress and success within program areas.

Working with companies seeking government contracts for scientific-oriented projects, including IT Cloud technology contracts for genomics research, and R&D contracts for biodefense vaccines. Provide scientific education and advice, and contribute to the preparation of contract proposals to RFPs.

Leading an immunology research and development group of scientists in infectious disease vaccine development.